We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Stockal+Disclaimer.pdf
41 own
32 watching
Current Price
$13.52
$-0.48
(-3.43%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
3,863.5M
52-Week High
15.9
52-Week Low
5.42
Average Volume
0.6M
Dividend Yield
--
P/E Ratio
--
Market Capitalization3,863.5M
52-Week High15.9
52-Week Low5.42
Average Volume0.6M
Dividend Yield--
P/E Ratio--
What does the Stockal+Disclaimer.pdf do?
Our mission is to improve health with technologies that transform the way that antibody-based therapies are discovered. We aim to become the centralized operating system for next generation antibody discovery. Our full-stack, artificial intelligence-, or AI, powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. --- We were incorporated in 2012 under the Business Corporations Act (British Columbia), or the BCBCA. Our principal executive offices are located at 2215 Yukon Street Vancouver, British Columbia, V5Y 0A1, Canada and our telephone number is (604) 559-9005. We have six wholly owned subsidiaries, Lineage, a Delaware corporation, Trianni, a California corporation, AbCellera US Holdings Inc., a Delaware corporation, AbCellera Properties Inc., a BCBCA company, AbCellera Properties Columbia Inc., a BCBCA company, and Channel Biologics Pty Ltd., a proprietary company registered in New South Wales, Australia. Our website address is www.abcellera.com.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
Business Wire
16days ago
AbCellera (Nasdaq: ABCL) today announced the release of new data on its T-cell engager (TCE) platform at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, to be held virtually and at the Boston Convention & Exhibition Center from November 8 to 12, 2022. AbCelleras poster...
Business Wire
24days ago
AbCellera (Nasdaq: ABCL) announced today that Regeneron has elected to exercise its right to advance a therapeutic antibody candidate, discovered in partnership with AbCellera as part of a multi-target collaboration between the companies, into further preclinical development. The partnership, which...
Business Wire
5 months ago
AbCellera (Nasdaq: ABCL) today announced that Eli Lilly and Company (Lilly) has entered into a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab, the second antibody developed through AbCelleras collaboration with Lilly, for approximately...
Business Wire
6 months ago
AbCellera (Nasdaq: ABCL) and Empirico Inc. (Empirico) announced today that they have expanded their strategic multi-target discovery collaboration, which leverages Empiricos Precision Insights PlatformTM to discover genetically validated drug targets and AbCelleras technology to identify lead...
Ticker Report
6 months ago
Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its stake in AbCellera Biologics Inc. (NASDAQ:ABCL Get Rating) by 100.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 14,154 shares of the company...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$13.52
$-0.48
(-3.43%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00